



The 3 major factors controlling the rate of erythro-
poiesis and at the core of the pathogenesis of the 
anemia of chronic disease include: 
1. the bone marrow with all its ceIl and growth 
factor machinery 
2. erythropoietin (EPa) 
3. iron 
Iron metabolism will be addressed in Chapter 2.2. 
Other important co-factors, such as folate and vi-
tamin B12, will not be discussed here, because they 
are not part in the pathogenesis of the anemia of 
chronic disêases (w Chapter 2.3.). 
2.1.1. Erythropoiesis 
Human erythrocytes have a mean lifespan ofabout 
120 days. This implies that approximately 200 bil-
lion new erythrocytes, carrying collectively 6 g of 
hemoglobin, are produced per clay, Le. 2-3 million 
new red cells every second. The principal function 
afmature erythrocytes is to transport oxygen from 
the lungs to other body tissues. In situations ofane-
mia, which decreases oxygen supply, red cell pro-
duction can expand up to 20 times over baseline 
rates, underlying the very dynamic nature of 
erythropoiesis. One can distinguish 3 stages of 
erythropoiesis during development.'The first stage 
corresponds to primitive embryonic erythropoi-
esis that takes place in blood islands within the yolk 
sac and is characterized by EPO-independency. 
The second stage corresponds ta defmitive ery-
thropoiesis in the fetal liver. In the third stage, 
adult erythropoiesis results from the migration of 
hematopoietic~ stem cells to the bone marrow. 
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Figure2.1: Erythropoiesis. Erythropoiesis is a pro-
cess of continuous cell proliferation and differentia-
tian that ean be schematica!!y separated into progeni-
tors, preeursor cells and mature red cells, most of 
which express EPO receptors (EPO-Rl. The earliest pro-
genitor totally committed ta the erythroid lineage is 
the burst-forming unit-erythroid (BFU-El that evalves 
into colony-forming unit-erythroid ((FU-El. The earli-
est erythroid precursor is the pro-erythroblast, fo!-
lowed by basophilie erythroblast, polychromatophilic 
erythroblast and orthochromatic or acidophilic ery-
throb!ast. The changes in cytoplasm appearance re-
flect 'the progressive accumulation of hemaglobin. 
Sufficiently mature erythroblasts expulse their nucleus 
and become retieulocytes. Two days later the reticulo· 
cytes have losttheir RNA and become fully mature red 
blood cells (RBC). 
.. Erythroid cells 
Erythropoiesis is a process of continuous cell pro- . 
liferation and differentiation that can be schemati-
cally separated into 4 compartments, i.e. stem cells, 
progenitors, precursor cells and mature red ceUs 
(1& Figure 2.1). Stem cells are rare, primitive cells 
that are both capable of self-renewal and of differ-
entiation into ail blood cell lineages, qualifying 
them as multipotential cells. Commitment to dif-
ferentiation into one or more lineages generates 
progenitor cells. The progenitor ceil compartment 
comprises colony-forrning units of mixed lineage 
(CFU -mix), followed by a bipotentia! megakaryo-
cytic-erythrocytic progenitor. The earliest proge-
nitor totally committed to the erythroid lineage is 
the burst-fonning unit-erythroid (BFU-E) that 
forms large bursts of erythroblast colonies within 2 
weeks in semi-solid culture. BFU-E evolves into 
colony-forming unit-erythroid (CFU-E) that 
forms single colonies of up to 64 erythroblasts 
within a few days in semi-solid cultures. The ery-
throid precursor ceIl compartment comprises 
~--
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bone marrow ceUs that are easily recognized under 
the microscope. The earliest erythroid precursor is 
the pro-erythroblast, foilowed by basophilie ery-
throblast, polychromatophilic erythroblast and 
orthochromatic erythroblast. The changes in cyto-
plasm appearance reflect the progressive accumu-
lation of hemoglobin whose production is made 
possible through strong expression of transferrin 
receptors facilitating iron acquisition. Cell division 
ends at the polychromatophilic stage. Then suffi-
ciently mature erythroblasts expulse their nucleus 
and become reticulocytes that are still actively pro-
dudng hemoglobin in the circulation. Two days 
later the reticulocytes have lost their RNA and be-
come fully mature red blood cells. 
l1li Growth factors 
The whole process of erythropoiesis is strongly in-
fluenced by a number of cytokines and gruwth fac-
tors that affect the survival, proliferation and mat-
uration of erythroid progenitors. Most of these 
growth factors are produced in the bone marrow 
micro-environment that comprises stromal cells 
(fibroblasts, endothelial ceils) , accessories ceils (T-
cells) macrophages) monocytes) and a protein-car-
bohydrate scaffold that forms the extracellular ma-
trix. The major growth factors that regulate ery-
thropoiesis include both positive regulators and 
negative regulators. The major positive regulators 
are stem cel! factor (SCF), Flt-3 ligand (Flt-3L), 
thrombopoietin (TPO), interleultin-11 (IL-11), 
IL-3) granulocyte-monocyte colony-stimulating 
factor (GM-CSF) and erythropoietin (EPO). EPO 
is the major positive regulator and will be de-
scribed in more details below. Indeed, EPO and 
EPO receptors appear to be required for defmitive 
erythropoiesis and the terminal phases of erythro-
poietic differentiation. SeF and FIt-3L are early-
acting growth factors that promote the survival 
and proliferation of early progenitors) but SCF is 
also the major growth factor for BFU-E. Besides its 
action on the megakaryocytic lineage) thrombo-
poietin also influences early progenitors up to the 
stage ofBFU-E. IL-3 and GM-CSF act on more ma-
ture progenitors of ail myeloid celilineages, in-
cluding BFU-E. Contrarily to EPO that is abso-
lutely required for red ceIl differentiation) ail these 
growth factors mostly impact on progenitor cen 
survival and proliferation and rather prevent ceil 
differentiation. The process of erythropoietic dif-
ferentiation involves a complex netv.,rork of tran-
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scription factors (1). Among them, GATA-I plays 
a major role by binding to GATA-binding sites 
present in the promoters and/or enhancers of ail 
erythroid-specific genes (2), explaining its essen-
tial function both in erythroid survival and matu-
ration. Other transcription factors, such as FOG-l) 
exert their activity through protein-protein inter-
actions) with FOG-l bindingto GATA-l. Another 
important transcription factor is Tal-l that forms 
transcriptional complexes with other transcription 
factors. 
.. Negative regulators 
Multiple apoptotic mechanisms are strongly in-
volved in the negative regulation of erythropoiesis) 
explaining the small baseline level of ineffective 
erythropoiesis (1). EPO deprivation or stimulation 
of death receptors result in activation of caspases-
3, -8 and -ID, which then lead to cleavage of the 
transcription factors GATA-l and TAi-l) thereby 
triggering apoptosis. However, caspase activation 
plays also an important role in the normal process 
of erythroid maturation. Cell death receptors and 
their ligands belong to the TNF receptor and TNF 
superfamilies) respectively. The Fas/Fas ligand 
(FasL) system is involved in a regulatory feedback 
mechanism exerted by mature erythroblasts 
against immature erythroblasts. Erythroid colony-
forming cells express low levels of Fas. However, 
Fas is upregulated in early erythroblasts and this 
high expression is maintained through terminal 
differentiation) while expression of FasL is selec-
tively induced in late differentiating erythroblasts. 
However) FasL-mediated ceil death is only effec-
tive in less mature erythroblasts where it is antago-
nized by high doses ofEPO. lndeed EPO mediates 
erythroid expansion during an erythropoietic 
stress by suppressing Fas/FasL coexpression. 
GATA-I and Tal-I cleavage appears to be respon-
sible for Fas-mediated apoptosis (in 9the absence of 
EPO) and maturation blockage (in the presence of 
EPO). TNF-related apoptosis-inducing ligand 
(TRAIL) is also a negative regulator of normal 
erythropoiesis. TRAIL receptors are expressed 
more densely on immature compared to mature 
erythroblasts) while TRAIL is preferentially ex-
pressed by mature erythroblasts, a pattern very 
similar to that of the Fas/FasL system. TRAIL seIec-
tively decreases the number of glycophorin A in-
termediate erythroblasts without affecting imma-
ture or more mature erythroblasts. TYVEAK) an-
other member of the TNF superfamily, is also able 
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to Înhibit erythroid ceIl gwwth and differentiation 
through caspase activation. 
2.1.2. Erythropoietin 
III Regu/ation of EPO production 
It has been known for a long time that EPO pro-
duction is regulated by a feedback mechanism 
through which anemia-induced hypoxia stimu-
lates EPO secretion in the circulation that in turn 
corrects the hypoxia by stimulating the generation 
of additional red ceUs ( ... Figure 2.2). Polycy-
themia induced by transfusion or prior exposure 
to hypoxia increases mause sensitivity to EPO 
through rêduction in endogenous EPO produc-
tion. From its serum concentration of about 
20 mU/ml and its serum half-life of about 7-8 
hours, it can be estimated that baseline endoge-
nous EPO production amounts to about 
3 UJkglday. In response to hypoxia, EPO levels in-
crease after about 60-90 minutes, peak after about 
20 hours and then decrease to an intermediate 
steady state level that is proportional to the severi ty 
of hypoxia (3). Metabolic factors a1so influence 
EPO levels) suggesting that increased oxygen de-
mand aiso stimulates EPO production. Oxygen-
sensing mechanisms are operative in anemic hy-
poxia (tissue hypoxia -with normal arterial oxygen 
tension) as weIl as hypoxic hypoxia (tissue hypoxia 
witb decreased arterial pO,) (3). Thus it appears 
that regulation ofEPO production is based on tis-
sue oxygen tension. Cobalt also stimulates EPO se-
cretion. Bence) one unit of erythropoietin was de-










Figure 2.2: EPO physiology. (A) EPO production ÎS 
regulated by a feedback mechanism through which 
anemia-induced hypoxia stimulates EPO secretion 
that in turn corrects the hypoxia by stimulatîng the 
generation of addîtional red cells. (8) Therefore, serum 
EPO levels increase exponentîallywhen an anemia de-
velops. 
2. Pathophysiology 
III Site of EPO production 
Nephrectomy experiments identified the kidney as 
the major site of EPO production. The liver was 
later recognized as a secondary souree ofEPO, par-
ticularly during fetal development. EPO and EPO 
reeeptors are -widely expressed in many non-ery-
throid tissues, including the brain, and appear to 
be involved in local tissue protection from ische-
mia and hypoxic damage. Bowever this small a-
mount ofEPO production outside of the liver and 
kidney does not contribute to the endocrine func-
tion of EPO. The human EPO gene was cloned in 
1985. This advance allowed the identification of 
EPO-producing celis as corticalinterstitiaI celis ad-
jacent to proximal tubules in the kidney. These 
cells were identified as fibroblasts. Only a minority 
of renal interstitial fibroblasts expresses EPO 
mRNA even during severe hypoxia. These peri-
tubular fibroblasts generate EPO jn a all-or-none 
fashion so that EPO production can only be in-
creased through recruitment of additional celIs. In 
the liver, EPO is produced by hepatocytes and in-
terstitial cells that feature the same type of recruit-
ment in response to hypoxia. Studies in human 
hepatoma celllines showed that EPO-producing 
celis were the same as oxygen-sensing cells. 
III EPO and hypoxia 
VVhen the degree of anemia worsens) the area of 
EPO-producing celis spreads from the inner cortex 
to the entire cortex in the kidney and from the cen-
tral venous area towards the portal area in the liver. 
The gradient ofEPO production in the livermaybe 
explained by an inverse gradient of oxygen tension 
that is minimal in the pericentraI part of the he-
patic lobe. The oxygen gradient in the kidney cor-
tex results from high oxygen consumption toge-
ther with restricted oxygen delivery because close 
contact aliows oxygen to diffuse directIy from ar-
teries to veins before reaching the tubular capillar-
ies. A major determinant of renaI oxygen con-
sumption lS tubular sodium reabsorption that is 
proportional to the glomerular filtration rate, 
which in tum depends on renal blood flow. There-
fore, renaI blood flow does not impact consider-
ablyon EPO production, sinee it influences oxygen 
supplyand oxygen consumption in parallel. 
.. EPO gene regu/ation 
TheEPO gene is located on chromosome 7, encod-
ing for a polypeptide with 193 amino-acids that IS 
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cleaved during secretion to release an EPO protein 
1Nith 165 amino-acids in the circulation. The regu-
lation of the erythropoietin gene has been studied 
in details (4). EPO secretion mostly depends on 
EPO mRNAlevels, which primarily result from in-
creased EPO transcription, but also enhanced 
mRNA stability. Hypoxia response elements are 
found not only in the EPO enhancer sequence but 
aiso in the close vicinity of many other genes regu-
lated by oxygen. This suggests the existence of a 
common oxygen-sensing mechanism both in 
EPO-producing celis in the kidney and liver, but 
also in many other cells where it regulates a variety 
of other processes (3). In response to hypoxia, EPO 
transcriptionis increased through the involvement 
ofan enhancer element located 3" to the EPO gene. 
At the core of this pro cess is the hypoxia-inducible 
transcription factor (HIF) (5). HIF consists of a 
heterodimer of an oxygen -regulated a subunit and 
a constitutive p subunit (6). HIF-la. forms a tran-
scription factor complex binding to the EPO en-
hancer element. HIF-la is rapidly induced by hy-
poxia and CoCb, but also deferoxamine, suggest-
ing that oxygen sensing involves an iron-contaÎ-
ning protein. Upon resolution ofhypoxia, HIF-la. 
is rapidly ubiquitinated and degraded in protea-
somes after binding to the von Hippel-Landau 
(VHL) protein. Binding of HIF-la to the VHL 
protein depends on the hydroxylation of2 specific 
prolines. HIF-la proline hydroxylation is itselfre-
liant on a non-herne iron-containing hydroxylase. 
Therefore, the following regulatory mechanisrn 
has been identified. In hypoxia, HIF-Ia. is not 
hydroxylated, does not bind to the VHL protein 
and thus persists to ensure continued EPO pro-
duction. In the presence of oxygen, HIF-la. is rap-
idly hydroxylated, enabling it to bind to the VHL 
protein that targets Îtfor ubiquitination and degra-
dation in the proteasome. In addition, oxygen-
dependent hydroxylation of HIF-la on an aspa-
ragioe by another hydroxylase (Factor-inhibiting 
RIF-l or FlH) inhibits binding to another protein 
ID the HIF-l a. transcription complex, thereby pre-
venting it from playing its enhancing role in EPO 
gene transcription. Other sequences that are 10-
cated 5' to the coding sequence may be also in-
vo1:ed in the regulation ofEPO transcription. Ne-
gatIVe regulators of EPO gene expression include 
:ATA-2 and NF-KB. GATA-2 is a transcription 
actor that binds to the EPO promoter in the 5' 
.' .. 
-----'"~_..:.~ __ ~ccc-~iIitiii 
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flanking region of the EPO gene. GATA-2 DNA-
binding is reduced under hypoxic condition. NF-
KB also inhibits the EPO promoter. Gene suppres-
sion by NF-KB may be explained by competition 
between NF-KB and other transcription factors for 
the co-factors p300/CBP that are critîcally invol-
ved in hypoxia-induced EPO expression. 
.. EPO receptor (EPO-R) 
The EPO-R belongs to the cytokine cIass 1 receptor 
superfamily (5). EPO signailing involves numer-
ous proteins, including JAK2 that chaperones 
EPO-R to the plasma membrane, kinases involved 
io the P13K, AKT kinase and Ras pathways, and the 
signal transducer and activator of transcription 
Stat-5 that influences the expression of several 
genes controlling cell prolif~ration and differentia-
tion ap.d activates the expression of several anti-
apoptotic genes in erythroid ceils. EPO binding to 
EPO-sensitive cells results in incrèased DNA and 
RNA synthesis, glucose uptake, globin gene tran-
scription, transferrin receptor expression and he-
moglobin production. CFU-E is the most EPO-
sensitive œil, while BFU-E is not. Rather than a 
proliferation factor, EPO appears to be mostly a 
survival facto,! that prevents apoptosis of CFU -E 
through basophilie erythroblasts. 
III Serum EPO levels 
Serum EPO levels may vary considerably (7). Le-
vels are usually between 10 and 20 mU/ml in nor-
mal subjects, may decrease sornewhat in primary 
polycythemia, but increase exponentially when an 
anemia develops below an Hct of30-35 % (I@" Fi-
gure 2.2). Therefore, a serum EPO value must al-
ways be evaluated in relation to the degree of ane-
mia. From the relationship between Hct and EPO 
in normal subjects and patients with hemolytic 
anemia, it is possible to derive 95 % confidence 
limits (0.80-1.20) for the O/P ratios of observedl 
predicted log (EPO) (8). EPO leveIs inappropri-
ately low for the degree of anemia (O/P <0.80) are 
encountered in renal failure, but aiso in a number 
of other conditions, including the anemia of chro-
nic disease. Inappropriately high serum EPO leveis 
(O/P > 1.20) are seen in secondarypolycythemia, a 
feature permitting its separation from primmypo-
lycythemia. In addition, one should take into ac-
count the inverse relationship between marrow 
erythropoietic activity and serum EPO levels: the 
higher the number of erythroid precursors, the 
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lower the serum EPO value. Hence serum EPO lev-
els are the result of a balance between the rate of 
EPO production and its utilization by the ery-
throid marrow. 
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2.2. Iron deficiency 
Iron deficiency is the most important pathophy-
siological mechanism leading ta anemia in IBD. It 
occurs in over one third of the patients suffering 
from Crohn's disease or ulcerative colitis (1). Iron' 
metabolism is an active research field and recent 
advanceshave been made in understandingpatho-
physiological processes involved in the regulation 
of iron homeostasis. 
2.2.1. Physiology of iron metabolism 
III Iron absorption 
Iron is an essential elernent for most organisms 
from prokaryotes to mammals, being a part of nu-
merous enzymes partidpating in redox reactions 
or oxygen delivery (2-4). The major source ofiron 
is food, where it cornes in the form ofheme-bound 
or non-herne iron. Iron absorption occurs only in 
the duodenum and upper jejunum. Heme-bound 
ITon has a eonsiderably higher bioavailability than 
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non-herne iron. Herne, released proteolytically 
from myoglobin and hemoglobin (mostly from 
meat), binds ta the herne carrier protein HCP-l 
and enters the mucosa epithelium unchanged via 
endoeytosis, where iron is subsequentlyfreed frorn 
the complex by the low pH; however, this pro cess 
has not yet been studied in detai!. 
More is known about the absorption of non-herne 
ITon. Most iron is available in the form of ferrie 
(Fe3+) ions, whieh do not readily pass the mucosal 
barrier; therefore a reduetion to ferrous ions (Fe2+) 
is needed to facilitate transport. Reducing agents 
are present in the food itself, the rnost cornmon ex-
ample being vitamin C. An additional mechanism 
utilizes the membrane-bound ferrireductase 
DcytB (duodenal cytochrome B). Ferrous iron 
then passes through the brush-border membrane 
via the divaient metal transporter DMT-1, which 
operates via a proton electrochemical gradient (2, 
4-6). 
Severa} factors influence iron uptake in the gut 
mucosa, among them the form of iron and its re-
dox state in the food, the pH in the intestinal lu-
men, the presence of chelating agents in the food 
(e.g. phytic add, oxalic acid) and the expression 
levels ofDMT-1 in the epithelial cells. As a conse-
quence, only a small percentage of the ingested 
iron (physiologically 1-2 mg per day) is absorbed 
(6). 
Once ITon has entered the ceIl, it is either used for 
metabolic purposes, incorporated into the iron 
storage protein ferritin, or is released Înto the cir-
culation for the needs of the orgamsm. The exact 
pathway by which iron crosses the guI epithelial 
ceil from the apical brush border ta the basolateral 
side has not been clarified sufficiently. Both tran-
scytosis as weil as a participation of Iron chaperone 
proteins have been suggested to play a role in this 
process (7, 8). Once iron reaches the basolateral 
surface, it leaves the enterocyte via ferroportin and 
is packed into the iron transport protein trans-
ferrin to enter the circulation. Prior to binding ta 
transferrin, the ceruloplasmin - related copper-
containing membrane-bound ferroxidase he-
phaestin oxidises Fe2+ baek to Fe3+ (6) (summa-
rized in Figure 2.3). 
